Review Papers Against Their Own Results

Concise appraisal

The review argues that accelerated eryptosis contributes to anemia and hypercoagulation in liver diseases, pointing to bilirubin and bile acids as major circulating triggers and to phosphatidylserine exposure as a central mediator — but the human clinical evidence is limited, heterogeneous, and often indirect, so causal claims remain provisional

Key citation: Kurmangaliyeva et al review

Eryptosis in Liver Diseases: Critical review and synthesis

Paper Kurmangaliyeva S et al., Eryptosis in Liver Diseases: Contribution to Anemia and Hypercoagulation, Medical Sciences, DOI 10.3390/medsci13030125 (2025) — systematic literature synthesis up to June 2025 focused on mechanisms, triggers, disease associations, and therapeutic implications.

Main claims summarized (verbatim evidence)

• Review conclusion on eryptosis role
• Evidence linking bilirubin to eryptosis

Detailed critique

1) Strengths

• Comprehensive literature collation to June 2025, with mechanistic integration (Ca2+ influx, ceramide, ROS, PS exposure) linking liver metabolites to known eryptotic signaling pathways — accurately synthesized from multiple experimental reports (Mechanistic synthesis).
• Useful tables summarizing doses and signaling features for metabolites (bilirubin, bile acids, CRP, fatty acids) and drugs that induce eryptosis — practical for experimental planning (Useful dosing tables).

2) Weaknesses and limitations

1. Evidence mixture and translation gap: most mechanistic work cited is from in vitro RBC exposures and small animal models (rabbit, mouse bile-duct ligation). The review repeatedly notes limited human clinical datasets and heterogeneity (e.g., one clinical series n=27) — this limits causal inference for human liver disease patients (Limited human evidence).
2. Conflicting reports not fully reconciled: the review cites studies with opposite findings (Mei et al vs Wu et al on PS exposure in HB/cirrhosis) but does not perform meta-analysis or quantitative bias assessment to explain discrepancies (Conflicting human studies).
3. Dose relevance and physiological plausibility: several in vitro trigger concentrations are high (bile acids 0.3 mM, glycochenodeoxycholic acid ≥500 µM, conjugated bilirubin >3 mg/dL or bilirubin/albumin ratio ≥1) — the paper would benefit from explicit comparison to human plasma concentrations across liver disease stages, variability with protein binding, and whether RBC exposure in vivo reaches those free concentrations (Reported in vitro doses).
4. Mechanistic incompleteness: the review emphasizes PS-dependent outcomes (efferocytosis, procoagulant activity) but admits PS-independent mechanisms are unexplored — there is limited exploration of how erythrocyte membrane remodeling, microvesicle formation, or metabolic exhaustion of erythropoiesis contribute to anemia/coagulopathy in chronic liver disease (PS focus and gaps).
5. Therapeutic recommendations are speculative: suggestions to target exposed PS or identify anti-eryptotic hepatoprotective compounds (for example wogonin) are forward-looking but lack preclinical efficacy data in disease-relevant in vivo liver-disease models with clinically meaningful endpoints (anemia, thrombosis, fibrosis progression) (Therapeutic speculation).

3) Specific methodological suggestions the authors could add

• Quantitative meta-analysis and pre-specified subgrouping by disease (ALD vs NAFLD/MASLD vs cholestatic vs viral) for human PS exposure studies.
• Pharmacokinetic comparison: map reported in vitro trigger concentrations to measured human free (unbound) bilirubin and bile acid concentrations across liver disease stages.
• Propose standardized eryptosis measurement protocols (flow cytometry staining gates for annexin V, Ca2+ dyes, ATP assays) and reporting checklists to reduce heterogeneity.
• Recommend longitudinal clinical cohorts measuring erythrocyte PS exposure, microparticle counts, hemoglobin dynamics, and thrombotic events to evaluate temporal and causal links.

Reproducibility and evidence strength

The review is a well-referenced narrative/systematic synthesis but relies heavily on heterogeneous primary studies (in vitro exposures, animal models, small human cohorts). The authors appropriately acknowledge limitations. The core mechanistic chain (bilirubin/bile acids → Ca2+ influx/ceramide → PS exposure → erythrophagocytosis/procoagulant activity) is biologically plausible and supported by experimental work, but robust human causal evidence is currently moderate-to-weak.

Acknowledged evidence gaps

Practical takeaways for researchers

• When designing experiments, match in vitro trigger concentrations to clinically observed unbound metabolite levels and consider albumin binding for bilirubin/bile acids.
• Report erythrocyte PS exposure alongside functional coagulation assays (thrombin generation, clot structure) to connect cellular phenotype to systemic procoagulant state.
• Use longitudinal human cohorts to test whether eryptosis markers predict anemia progression or thrombotic events independent of known confounders (nutrition, bleeding, infection, bone marrow suppression).

Visual synthesis (interactive)

Conclusions and confidence

Conclusion: the paper successfully consolidates mechanistic evidence that liver-derived metabolites (principally bilirubin and bile acids) and some drugs can induce eryptosis, and that PS exposure plausibly links eryptosis to anemia and hypercoagulation in liver disease. However, translation to robust causal claims in humans is premature because of limited, heterogeneous clinical data and dose/exposure uncertainties — overall confidence in the review conclusions is moderate (Authors call for more studies).

Author Review links

• Author Review Saulesh Kurmangaliyeva
• Author Review Kristina Baktikulova
• Author Review Anton Tkachenko
• Author Review Bibigul Seitkhanova
• Author Review Liliya Tryfonyuk
• Author Review Farida Rakhimzhanova
• Author Review Rustam Yussupov
• Author Review Kairat Kurmangaliyev